Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14101 - 14125 of 15018 in total
LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
Investigational
Investigational
DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene. It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.
Investigational
BBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and manufactured by Belief BioMed. It consists of an adeno-associated virus vector containing an expression cassette of the human Factor VIII transgene.
Investigational
Matched Description: … BBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and
Coagulin-B is an adeno-associated viral vector expressing human blood-coagulation Factor IX.[A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation.
Investigational
Matched Description: … , the manufacturing company discontinued the Phase I trial in 2004, halting its further development and
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
MaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.
Investigational
Thalagen is a branded product developed by San Rocco Therapeutics. It consists of autologous CD34-positive hematopoietic progenitor cells transduced with TNS9.3.55, a lentiviral vector encoding the normal human beta-globin gene. It is being investigated for the treatment of beta-thalassemia.
Investigational
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
Experimental
NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.
Experimental
Investigational
Investigational
MCMV5322A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with MCMV3068A to form RG7667.
Investigational
Investigational
MBL-HCV1 is a monoclonal antibody developed to prevent the recurrence of hepatitis C virus (HCV) in patients receiving a liver transplant.
Investigational
Octovalent O-polysaccharide-toxin A conjugate vaccine is currently being investigated to treat Pseudomonas Aeruginosa infection in patients with cystic fibrosis.
Investigational
Investigational
Displaying drugs 14101 - 14125 of 15018 in total